Elizabeth Gilbreath
Nurse Practitioner · Centre, ALNPI 1477572295
Payments from drug & device makers
Across 274 payments — averaging $14.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$741
- AbbVie$717
- AstraZeneca$501
- Lilly USA, LLC$254
- Merck$194
- Bayer$155
- plus $1K from 29 others
What the payments were for
- Food & beverage$3,887100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 75 | $741 |
| AbbVie | 57 | $717 |
| AstraZeneca | 27 | $501 |
| Lilly USA, LLC | 16 | $254 |
| Merck | 11 | $194 |
| Bayer | 9 | $155 |
| Pfizer | 9 | $154 |
| Novo Nordisk | 8 | $135 |
| Dexcom, Inc. | 6 | $102 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $75 |
| Boehringer Ingelheim | 5 | $72 |
| Amgen | 4 | $71 |
| Otsuka America Pharmaceutical, Inc. | 3 | $61 |
| Amarin Pharma, Inc. | 3 | $56 |
| Almatica Pharma LLC | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
| Novartis | 3 | $47 |
| Adlon Therapeutics L.p. | 3 | $44 |
| Biohaven Pharmaceuticals, Inc. | 3 | $43 |
| Supernus Pharmaceuticals, Inc. | 2 | $40 |
| Verona Pharma, Inc. | 2 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Astellas Pharma US Inc | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| Exact Sciences | 1 | $25 |
| Genentech USA, Inc. | 2 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Redhill Biopharma Inc. | 1 | $19 |
| Lantheus Medical Imaging, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Allegis Pharmaceuticals, LLC | 1 | $14 |
| Galt Pharmaceuticals, LLC | 1 | $4 |
How this compares
$3,887 in reported general payments places this provider in the 85th percentile of 1,505 nurse practitioner providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 115 | $96,825 |
| OzempicSemaglutide | 77 | $95,207 |
| TrulicityDulaglutide | 59 | $69,750 |
| JardianceEmpagliflozin | 62 | $68,845 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $61,233 |
| XareltoRivaroxaban | 56 | $47,780 |
| FarxigaDapagliflozin Propanediol | 42 | $43,419 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 55 | $41,670 |
| JanuviaSitagliptin Phosphate | 41 | $41,520 |
| MounjaroTirzepatide | 24 | $33,015 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $20,525 |
| LinzessLinaclotide | 23 | $17,043 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $11,209 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $10,812 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 13 | $9,286 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $254 | $102,76583 claims |
| PfizerEliquis | $154 | $96,825115 claims |
| Novo NordiskOzempic | $135 | $95,20777 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $501 | $91,202121 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $741 | $72,04590 claims |
| Boehringer IngelheimJardiance | $72 | $68,84562 claims |
| Johnson & JohnsonXarelto, Invokana | $16 | $53,97267 claims |
| MerckJanuvia, Janumet Xr, Lagevrio (Eua) | $194 | $53,63767 claims |
| AbbVieLinzess | $717 | $17,04323 claims |
| Astellas Pharma US IncMyrbetriq | $28 | $7,15316 claims |
| Teva Pharmaceuticals USA, Inc.Albuterol Sulfate | $25 | $2,32712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,505 nurse practitioner providers in Alabama.
Other nurse practitioner in Centre
- Erin TannerAlabaster$141K
- Ardie Pack MabienMobile$126K
- Ginger McDanielBirmingham$27K
- Audrey MorganMontgomery$24K
- Hollie CrutchfieldDothan$22K
- Leah GravesBirmingham$21K
- Lauren DowneyBirmingham$19K
- Ashley HodgensMontgomery$19K
- Lisa PeoplesBirmingham$17K
- Samantha WeaverBirmingham$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.